Becton Dickinson Microbiology Systems licenses Alamar Biosciences technology:
This article was originally published in Clinica
Executive Summary
Becton Dickinson Microbiology Systems is to acquire a semi- exclusive, worldwide licence to Alamar Biosciences' alamarBlue technology. Under a letter of intent signed by the two companies on May 8th, Alamar would receive up to $3.5 million and undisclosed royalties on product sales incorporating the technology. Alamar, which is to merge with AccuMed to form AccuMed International (see Clinica No 652, p 15), says the agreement with Becton Dickinson will double its own distribution capabilities. AccuMed International will retain rights to use the alamarBlue technology in any of its own commercial products.